Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$407.04 USD
-3.85 (-0.94%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $407.05 +0.01 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
ELV 407.04 -3.85(-0.94%)
Will ELV be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ELV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELV
Elevance Health Declines 20% in 3 Months: Time to Sell the Stock?
Beyond UnitedHealth's Q3 Earnings: Time to Reevaluate & Sell Stock?
ELV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Elevance Health, Doximity and HealthEquity
Elevance Health's Q3 Earnings Miss Due to Medicaid Redeterminations
3 Medical Services Stocks to Buy to Navigate Industry Challenges
Other News for ELV
Leon Cooperman's Strategic Exits and Key Increases Highlight Q3 2024 Moves
Omega exits stakes in Devon, Las Vegas Sands, KBR, and Paramount Global
Omega exits stakes in Devon, Las Vegas Sands, KBR, and Paramount Global
Medicare to adjust disputed Star Ratings measure: Bloomberg News
Medicare to adjust disputed Star Rating measure: Bloomberg News